Latest Conference Articles

RWE Demonstrates Robust PSA Response and Treatment Adherence of Apalutamide in CRPC

September 10th 2021, 8:53pm

American Urological Association Annual Meeting

Patients with nonmetastatic castration-resistant prostate cancer demonstrated high adherence rates and favorable prostate-specific antigen response to apalutamide according to real-world evidence presented at the 2021 American Urological Association Annual Meeting.

Elevated Antibody Titers May Predict Nadofaragene Firadenovec Durability in BCG-Unresponsive NMIBC

September 10th 2021, 8:48pm

American Urological Association Annual Meeting

Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec for the treatment of patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.

Atezolizumab plus Chemotherapy Displays Efficacy, Tolerability in NSCLC with Untreated Brain Metastases

September 10th 2021, 8:31pm

IASLC World Conference on Lung Cancer

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

Elranatamab Alone or Plus Lenalidomide Shows Early Efficacy, Safety in Heavily Relapsed Myeloma

September 10th 2021, 8:29pm

International Myeloma Workshop

Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

September 10th 2021, 8:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

Rituximab-Bendamustine Combo Induces Superior Outcomes Over Other Regimens in Waldenström Macroglobulinemia

September 10th 2021, 7:57pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with fixed-duration rituximab plus the chemotherapy bendamustine was associated with more favorable outcomes than the triplet of dexamethasone, rituximab, and cyclophosphamide, as well as bortezomib, dexamethasone, and rituximab in patients with treatment-naïve Waldenström macroglobulinemia.

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma

September 10th 2021, 6:57pm

Society of Hematologic Oncology Annual Meeting (SOHO)

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

Cilta-Cel Emerges as Potential CAR T-Cell Option in Relapsed/Refractory Multiple Myeloma

September 10th 2021, 6:53pm

International Myeloma Workshop

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

Ide-Cel Maintains Clinical Activity With Long-Term Follow-Up in Relapsed/Refractory Multiple Myeloma

September 10th 2021, 6:31pm

International Myeloma Workshop

Idecabtagene vicleucel continued to elicit frequent, deep, and durable responses among patients with heavily pretreated relapsed/refractory multiple myeloma irrespective of whether patients received 3 or at least 4 prior therapies.

Talquetamab Continues to Impress in Relapsed/Refractory Multiple Myeloma

September 10th 2021, 5:41pm

International Myeloma Workshop

Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.

Challenges Remain in Treatment of Accelerated Phase Myeloproliferative Neoplasms

September 10th 2021, 5:03pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Dr. Sanchorawala on the Impact of Depth of Renal and Cardiac Response on Survival in AL Amyloidosis

September 10th 2021, 2:41pm

International Myeloma Workshop

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis. 

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

September 10th 2021, 12:04pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

TP53 and IGHV Status Retain Utility as Prognostic Markers in CLL

September 9th 2021, 9:45pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

Lurbinectedin/Doxorubicin Misses OS End Point in Relapsed SCLC, But Shows Superior Safety Vs SOC

September 9th 2021, 9:06pm

IASLC World Conference on Lung Cancer

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

Noncovalent BTK Inhibitors, CAR T-Cell Therapy Generate Excitement in CLL

September 9th 2021, 9:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Controlling Infections Could Be Key to Improving Survival in CLL

September 9th 2021, 8:56pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera

September 9th 2021, 8:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

Adjuvant Atezolizumab Improves DFS in Early-Stage NSCLC Across Most Disease Stages and Prior Therapies

September 9th 2021, 8:24pm

IASLC World Conference on Lung Cancer

Adjuvant atezolizumab improved disease-free survival over best supportive care in patients with PD-L1–positive, stage II to IIIA non–small cell lung cancer, with benefit observed across most subgroups analyzed, according to data from an exploratory analysis of the phase 3 IMpower010 trial.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

September 9th 2021, 7:46pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.